New MedPredict Report Reveals Top Alzheimer's Experts' Insights on Diagnostics and Treatments in Development Pipeline
Posted on: Friday, 12 June 2009, 09:35 CDT
MedPredict interviewed renowned Alzheimer's disease thought leaders to identify the most promising candidates in clinical development, as well as explore unmet needs. Interviews for this report were conducted following the 2009 American Academy of Neurology (AAN) conference.
"In this report, our panel of experts describes the clinical progress of the most interesting therapeutic and diagnostic candidates in the pipeline," according to
"The panelists rank the most promising small molecules and antibodies that are targeting amyloid and plaques, offering their opinions on gamma-secretase inhibitors and modulators, beta-secretase inhibitors, Tau phosphorylation inhibitors, cardiovascular agents, anti-amyloids and aggregation inhibitors, histone deacetylases (HDACs), SIRT-1, metal chelators and drugs like Dimebon, specifically designed to enhance mental function," says Berk. "They also update the progress coming out of ADNI, the Alzheimer's Disease Neuroimaging Initiative, and describe how some amazing diagnostic tools have now been incorporated into the pivotal trials of these exciting therapeutics."
Companies/partnerships discussed in this report: Abbott, Allon, Astellas/CoMentis, AstraZeneca/Banner, AstraZeneca/Takeda, AstraZeneca/Targacept, Avid, Baxter, Bayer-Schering/Avid Radiopharmaceuticals, Boehringer Ingelheim/Ablynx, Bristol-Myers Squibb, Elan/Transition Therapeutics/AZ, Elan/Wyeth, Envivo, Eisai, Forest/Merz/Lundbeck/Daiichi-Sankyo, GE Healthcare, GlaxoSmithKline, Lilly, Lilly/Elan, Link, Myriad, Novartis, Oligomerix, Pfizer, Pfizer/Medivation, Prana, Roche/Memory, Satori, TauRx, TauTaTis, Transtech, and Wyeth.
The full report may be purchased by contacting MedPredict.
About MedPredict
MedPredict (www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders. Based on primary interviews with these thought leaders, MedPredict publishes periodic therapeutic area reports to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and presentations, as well as clinical, regulatory and marketing activity.
SOURCE MedPredict
Source: PR Newswire
Related Articles
- Bapineuzumab To Become the First-to-Market Disease-Modifying Alzheimer's Drug After Flurizan's Discontinuation
- This Report Offers an Assessment of the Drivers and Inhibitors Affecting the Mobile eHealth Market
- CoMentis Receives FDA Clearance to Begin Human Clinical Trials for Its Disease-Modifying Alzheimer's Therapy
- Hicks Holdings Acquires 40 Percent Stake in SafeMed Inc., An Emerging Leader in Clinical Decision Support Systems
- $4 Trillion in Cost Savings to U.S. From New Disease-Modifying Alzheimer's Treatments
- Abbott/Eisai's Humira and UCB's Cimzia Will Drive Sales of TNF-Alpha Inhibitors to $1.3 Billion in the Market to Treat Crohn's Disease
- Avidia Initiates Trial of Crohn's Disease Inhibitor
- Valeant Pharmaceuticals Announces U.S. Availability of Cesamet(TM) (CII) and Initiates Post-Marketing Clinical Trial
- Two New Drugs for the Treatment of Alzheimer's Disease Are Expected to Enter the Market By 2008
- Prevalence of Cardiovascular Disease in the Seven Largest Pharmaceutical Markets With Forecasts 2004-2010
 |
 |
User Comments (0)
RSS Feeds